Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) entered into oversold territory, hitting an RSI ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

(RTTNews) - Apellis Pharmaceuticals, Inc. (APLS) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the supplemental New Drug Application ...

WALTHAM, Mass. - The U.S. Food and Drug Administration (FDA) has accepted Apellis Pharmaceuticals, Inc.’s (NASDAQ: APLS) supplemental New Drug Application (sNDA) and granted Priority Review ...

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – ...